Day: May 24, 2023

NOI in Q1 is up 15% year-over-year, totaling some NIS 525 million Same Property NOI in Q1 is up around 9% FFO (excluding senior housing) in Q1 is up 8% totaling some NIS 335 million. Total FFO is up 4% at around NIS 350 million Financial Highlights for Q1/2023NOI in Q1 totaled some NIS 525 million, up around 15% year-over-year. The increase mainly derives from the acquisition of Mall Hayam together with rent increases in malls, offices and data centers. Same Property NOI was up around 9% in Q1. FFO excluding senior housing totaled some NIS 335 million in Q1 compared with around NIS 310 million year-over-year, up some 8%. In Q1, the total FFO was approx. NIS 350 million, compared with around NIS 337 million year-over-year, up some 4%. Net profit attributable to the shareholders totaled approx. NIS 377 million in Q1 compared with around...

To Nasdaq Copenhagen A/S                        24th May 2023                                        Announcement no. 51/2023 Final terms for bonds to be listed 24thMay 2023 On 24th May 2023, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated February 21st, 2023. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely,Jyske Realkredit A/S www.jyskerealkredit.com Please observe...

The-European-Health-&-Fitness-Market-Report_PressRelease2  Agillic proudly announces its sponsorship of the highly anticipated European Health & Fitness Market Report 2023 by EuropeActive and Deloitte. This collaboration signifies Agillic’s commitment to supporting the health and fitness industry in achieving digitalisation, harnessing tech innovation, and effectively reaching its goals through personalised communication. The European health and fitness market has experienced a positive change in data collection and research, essential for the sector’s post-pandemic recovery. The latest market report highlights an increase in memberships from 56.2 million to 63.1 million (+12.3%) and a rise in the number of fitness clubs to 63,830. Total revenues have reached an impressive 28 billion Euros, with notable progress...

Orlando, FL, May 24, 2023 (GLOBE NEWSWIRE) — The Sustainable Green Team, LTD. (OTCQX: SGTM) (“SGTM” or the “Company”), a provider of environmentally conscious solutions in the arbor care, disposal, and recycling industries enters into a Purchase Agreement with New Earth Technologies PTE. LTD. (“New Earth”) to increase HumiSoil® production. The Purchase Agreement allows SGTM to obtain additional catalyst ingredients to manufacture HumiSoil® and other related products, enough to produce an additional 4 million cubic yards of HumiSoil®. New Earth has agreed to deliver the ingredients to SGTM’s west coast facility located in Forks, Washington. This arrangement also gives SGTM access to international markets for VRM Biologik products which are used to support food and water security programs globally. HumiSoil® is a humus rich soil...

ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treatment for Netherton Syndrome has reached 50% enrollment. The company’s open label study is investigating the safety and efficacy of QRX003 topical lotion in Netherton Syndrome patients who are currently receiving off-label systemic therapy, primarily biologic therapy, and is being conducted under an open Investigational New Drug (IND). Quoin announced it had dosed the first patient in its clinical trial in March 2023 and has now dosed its fifth patient out of a total of 10 patients that are expected to participate in this single-arm study. Quoin Pharmaceuticals CEO,...